Foundayo is the second GLP-1 weight-loss tablet to get FDA approval, following closely behind Novo Nordisk's dental Wegovy. The SURMOUNT-1 (Jastreboff et al., NEJM, 2022) test stands as a spots research study that brought tirzepatide to the leading edge for weight-loss in individuals without diabetes mellitus. The findings from this...